Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. It is a modified form of human GLP-1 with 94% structural homology, engineered with specific amino acid substitutions and a fatty acid chain that extends its half-life to approximately one week, enabling once-weekly dosing.
Originally developed for type 2 diabetes management, semaglutide has become one of the most extensively studied peptides in metabolic medicine. Clinical trials have demonstrated significant efficacy in glycemic control, weight management, and cardiovascular risk reduction, leading to multiple FDA approvals and establishing it as one of the most commercially successful pharmaceutical compounds in history.
GLP-1 Receptor Activation: Semaglutide binds to and activates GLP-1 receptors found in pancreatic beta cells, the gastrointestinal tract, heart, brain, and other tissues. This binding initiates intracellular signaling cascades that produce multiple physiological effects.
Glucose-Dependent Insulin Secretion: In pancreatic beta cells, GLP-1 receptor activation stimulates insulin secretion only when blood glucose levels are elevated, reducing the risk of hypoglycemia compared to older diabetes medications.
Appetite and Satiety Regulation: GLP-1 receptors in the hypothalamus and brainstem regulate food intake. Semaglutide activates these central pathways, reducing hunger and increasing feelings of fullness after meals.
Gastric Motility: The compound slows gastric emptying, which contributes to reduced postprandial glucose excursions and enhanced satiety following food consumption.
| Trial | Population | Key Findings | Year |
|---|---|---|---|
| SUSTAIN 1-6 | Type 2 Diabetes | HbA1c reduction of 1.5-1.8%; superior to comparators | 2015-2017 |
| SUSTAIN 6 | T2D with CV risk | 26% reduction in MACE (stroke, MI, CV death) | 2016 |
| PIONEER 1-10 | Type 2 Diabetes | Oral semaglutide effective; first oral GLP-1 | 2018-2019 |
| STEP 1 | Obesity (non-diabetic) | 14.9% mean weight loss vs 2.4% placebo at 68 weeks | 2021 |
| STEP 2 | Obesity + T2D | 9.6% weight loss; improved glycemic control | 2021 |
| STEP 3 | Obesity + lifestyle | 16.0% weight loss with intensive behavioral therapy | 2021 |
| STEP 4 | Weight maintenance | Continued treatment prevents weight regain | 2021 |
| SELECT | Obesity + CVD (non-diabetic) | 20% reduction in MACE; first CV indication for obesity drug | 2023 |
The STEP trial program established semaglutide 2.4mg as the most effective pharmacological treatment for obesity to date. Mean weight loss ranged from 14.9% to 17.4% of body weight across different trial populations. Approximately one-third of participants achieved weight loss of 20% or more, previously only achievable through bariatric surgery.
The SUSTAIN 6 trial demonstrated a 26% reduction in major adverse cardiovascular events (MACE) in patients with type 2 diabetes. The SELECT trial subsequently showed a 20% MACE reduction in non-diabetic patients with obesity and established cardiovascular disease, representing a paradigm shift in cardiovascular risk management through weight-centric approaches.
In type 2 diabetes populations, semaglutide consistently achieves HbA1c reductions of 1.5-1.8 percentage points, with a significant proportion of patients reaching target HbA1c levels below 7.0%. The glucose-dependent mechanism minimizes hypoglycemia risk while providing robust glycemic control.
Beyond weight and glucose, clinical trials have documented improvements in blood pressure, lipid profiles (reduced triglycerides, increased HDL), inflammatory markers, and liver fat content. These pleiotropic effects contribute to overall cardiovascular risk reduction.
First-line or add-on therapy for glycemic control with cardiovascular benefits
Long-term weight management in adults with BMI ≥30 or ≥27 with comorbidities
MACE reduction in patients with obesity and established cardiovascular disease
Ongoing trials investigating benefits in heart failure with preserved ejection fraction
Clinical trials evaluating efficacy in non-alcoholic steatohepatitis
Early research exploring potential neuroprotective effects and cognitive benefits
Extensive clinical trial database with over 10,000 patient-years of exposure. FDA-approved with well-characterized safety profile.
Nausea, vomiting, diarrhea, and constipation are common, especially during dose titration. Usually transient and diminish over time.
Mild reactions at injection site may occur. Generally well-tolerated with subcutaneous administration.
Black box warning based on rodent studies. Contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN 2.
Rare cases of acute pancreatitis reported. Discontinue if pancreatitis is suspected. Use caution in patients with history of pancreatitis.
Increased incidence of cholelithiasis and cholecystitis observed in clinical trials, particularly with rapid weight loss.
Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It is not recommended for use during pregnancy or breastfeeding. Patients should be monitored for symptoms of pancreatitis and thyroid tumors. Healthcare providers should review complete prescribing information before use.
Regulatory Status: Semaglutide is FDA-approved under three brand names: Ozempic (type 2 diabetes), Wegovy (chronic weight management), and Rybelsus (oral formulation for type 2 diabetes). In 2024, Wegovy received an expanded indication for cardiovascular risk reduction based on SELECT trial results.
The compound continues to be studied for potential applications beyond its current indications. Long-term data on sustained weight loss maintenance, effects on muscle mass, and outcomes in diverse populations remain areas of active investigation.
View our selection of research-grade semaglutide with verified purity documentation.
View Products →The information presented on this page is compiled from peer-reviewed scientific literature and clinical trial data for educational purposes only. This content does not constitute medical advice, diagnosis, or treatment recommendations. Semaglutide is a prescription medication that should only be used under the supervision of a qualified healthcare provider. Products sold by Peachy's Peptides are intended for research purposes only and are not for human consumption. Researchers should consult applicable regulations and institutional guidelines before conducting any research involving this compound.